Canakinumab, a monoclonal anti-IL-1β antibody, is currently approved for treating several forms of arthritis, CAPS, and FMF, and its efficacy in reducing cardiovascular events in atherosclerosis patients has been shown in the large CANTOS trial [149]. The gene discussed is IL1B; the disease is cryopyrin-associated periodic syndrome.